Early results of a randomized phase III trial of platinum-containing doublets versus a nonplatinum doublet in the treatment of advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer 08975.

Abstract

In the European Organization for Research and Treatment of Cancer randomized phase III trial (08975), 480 patients with advanced non-small cell lung cancer received the standard arm of cisplatin/paclitaxel or one of two experimental arms; gemcitabine/cisplatin or gemcitabine/paclitaxel. Cisplatin was given at 80 mg/m(2) on day 1, gemcitabine was administered at 1,250 mg/m(2) on days 1 and 8, and paclitaxel at 175 mg/m(2) as a 3-hour infusion on day 1, every 3 weeks. The cisplatin/paclitaxel and gemcitabine/cisplatin regimens were comparably active. The nonplatinum arm, gemcitabine/paclitaxel, was well tolerated, but had a trend toward lower median, 1-year, and progression-free survival compared with the standard arm. Further follow-up and analysis of quality of life may clarify this possible difference in treatment outcome.

• Authors: Giuseppe Giaccone, European Organization for Research and Treatment of Cancer Group
• Journal: Seminars in oncology (Semin Oncol) Vol. 29 Issue 3 Suppl 9 Pg. 47-9 (Jun 2002) ISSN: 0093-7754 [Print] United States
• PMID: 12094339 (Publication Type: Clinical Trial, Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: Copyright 2002, Elsevier Science (USA). All rights reserved.

Chemical References

• Deoxycytidine
• Paclitaxel
• Cisplatin
• Gemcitabine

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Carcinoma, Non-Small-Cell Lung (drug therapy)
• Cisplatin (administration & dosage)
• Deoxycytidine (administration & dosage, analogs & derivatives)
• Humans
• Lung Neoplasms (drug therapy)
• Paclitaxel (administration & dosage)
• Quality of Life
• Survival Rate
• Gemcitabine